Table 2.
Clinical Characteristics by Therapy Modality, at the Beginning of the Follow-up.
| Characteristics | Hemodialysis (n = 5330) |
Peritoneal dialysis ( n = 7178) |
P value |
|---|---|---|---|
| Chronic kidney disease cause, n (%) | <.001* | ||
| Hypertension | 1296 (24.3) | 1668 (23.2) | |
| Diabetes | 2163 (40.6) | 3377 (47.0) | |
| Obstructive | 383 (7.2) | 229 (3.2) | |
| Polycystic kidney disease | 105 (2) | 135 (1.9) | |
| Tubulointerstitial | 33 (0.6) | 43 (0.6) | |
| Glomerular | 397 (7.4) | 729 (10.2) | |
| Pyelonephritis | 12 (0.2) | 11 (0.2) | |
| Unknown | 610 (11.4) | 701 (9.8) | |
| Others | 331 (6.2) | 285 (4.0) | |
| Diabetes, n (%) | 2557 (48.0) | 3843 (53.5) | <.001* |
| Hypertension, n (%) | 4204 (78.9) | 5914 (82.4) | <.001* |
| Ischemic cardiovascular disease, n (%) | 673 (12.6) | 837 (11.7) | .107 |
| Cerebrovascular disease, n (%) | 176 (3.3) | 232 (3.2) | .867 |
| Heart failure, n (%) | 725 (13.6) | 963 (13.4) | .783 |
| Body mass index (kg/m2), median [IQR] | 23.4 [20.8, 26.2] | 24 [21.5, 26.8] | <.001* |
| Weight (kg) | 62 [54, 70.8] | 63 [54.8, 72] | .006* |
| Charlson index, n (%) | .110 | ||
| No comorbidity (score 0-1) | 1381 (29) | 2079 (30.5) | |
| Moderate comorbidity (score 2-3) | 2473 (51.9) | 3403(50) | |
| High comorbidity (score >3) | 914 (19.2) | 1325 (19.5) | |
| No Charlson index data, n (%) | |||
| Hemoglobin (g/dL), median [IQR] | 10.4 [9.1, 11.7] | 11.5 [10.2, 12.6] | <.001* |
| Phosphorus (mg/dL), median [IQR] | 4.1 [3.3, 5] | 4.4 [3.7, 5.3] | <.001* |
| Albumin (g/dL), median [IQR] | 3.8 [3.5, 4.1] | 3.5 [3.1, 3.9] | <.001* |
| Albumin <3.5 g/dL, n (%) | 1085 (22.4) | 2890 (41.2) | <.001* |
| Albumin 3.5 to <4 g/dL, n (%) | 2067 (42.7) | 2773 (39.5) | |
| Albumin ≥4 g/dL, n (%) | 1960 (34.9) | 1359 (19.4) | |
| No albumin data, n (%) | 488 (9) | 156 (2.2) | |
| Parathyroid hormone (pg/mL), median [IQR] | 152 [73, 298] | 217.7 [118, 366.2] | <.001* |
| Ferritin (ng/mL), median [IQR] | 328 [156.7, 587.5] | 303.1 [152, 563] | .004* |
| Iron (µg/dL), median [IQR] | 45.6 [33, 61.5] | 53.4 [38, 72.6] | <.001* |
| Platelet count, median [IQR] | 245 000 [197 000, 309 000] | 282 000 [227 000, 347 000] | <.001* |
| Lymphocyte count, median [IQR] | 2540 [1790, 3790] | 2680 [1920, 4400] | <.001* |
| Lymphocyte platelet ratio, median [IQR] | 94.8 [56, 133] | 99.7 [50.3, 137.7] | .022* |
| Use of erythropoiesis-stimulating agents (ESA) (IU/kg), median [IQR] | 6000 [4000, 12 000] | 6000 [4000, 8000] | <.001* |
| ESA resistance index, median [IQR] | 12 [7.4, 19.8] | 8.4 [5, 13.3] | <.001* |
| nPCR (g/kg/day), median [IQR] | 0.9 [0.4, 1.2] | 0.9 [0.6, 1.2] | .819 |
| Malnutrition Index Inflammation, median [IQR] | 0 [0, 3] | 0 [0, 3] | <.001* |
| Residual diuresis (mL/day), median [IQR] | 0 [0, 975] | 700 [320, 1250] | <.001* |
| No residual diuresis (≤100 mL/day), n (%) | 3093 (76.9) | 929 (23.1) | <.001* |
| No residual diuresis data, n (%) | 199 (4) | 109 (1.5) |
Note. IQR = interquartile range; nPCR = normalized protein catabolic rate.
*
Statistically significant.